GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins-Reference-Cited by-同舟云学术

GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins

Published:2020-07-21 Issue:17 Volume:63 Page:9045-9069
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Watson Robert J.,Bamborough Paul^ORCID,Barnett Heather,Chung Chun-wa^ORCID,Davis Rob,Gordon Laurie,Grandi Paola¹,Petretich Massimo¹,Phillipou Alex,Prinjha Rab K.,Rioja Inmaculada,Soden Peter,Werner Thilo¹,Demont Emmanuel H.^ORCID

Affiliation:

1. Molecular Discovery Research, GlaxoSmithKline, Cellzome GmbH, Meyerhofstrasse 1, 69117 Heidelberg, Germany

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c00614

Reference55 articles.

1. Place your BETs: the therapeutic potential of bromodomains

2. BET domain co-regulators in obesity, inflammation and cancer

3. Functions of bromodomain-containing proteins and their roles in homeostasis and cancer

4. Suppression of inflammation by a synthetic histone mimic

5. Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of a potent orally available pyrazolopyridone derivative as a novel selective bromodomain and extra-terminal domain (BET)-first bromodomain (BD1) inhibitor;Bioorganic & Medicinal Chemistry Letters;2024-09

2. Discovery of a potent, orally available furopyridine derivative as a novel selective bromodomain and extra-terminal domain (BET)-first bromodomain (BD1) inhibitor;Bioorganic & Medicinal Chemistry Letters;2024-09

3. Epigenetic modulation through BET bromodomain inhibitors as a novel therapeutic strategy for progranulin-deficient frontotemporal dementia;Scientific Reports;2024-04-20

4. Selective Transformation of 1,3‐Cyclooctadiene into Novel Functionalized Azaheterocycles, β‐Amino Esters, and Lactams by Means of Ring‐Rearrangement Metathesis;European Journal of Organic Chemistry;2024-03-15

5. Successes and challenges in the development of BD1-selective BET inhibitors: a patent review;Expert Opinion on Therapeutic Patents;2024-03-11